GUARDANT HEALTH INC

GH stock refers to the common shares of Guardant Health, Inc., a precision oncology company listed on the Nasdaq under the ticker GH. The company is known for its liquid biopsy tests and genomic profiling services used in cancer research and clinical care. Shares represent an ownership stake in the business and trade on a major U.S. exchange. For the latest GH price and market data, refer to the quote displayed on this page.

Recent performance for GH depends on the latest market session and cannot be stated without up-to-date data. The stock's movement reflects investor reactions to Guardant Health's quarterly results, reimbursement developments, clinical study updates, and broader market conditions. To see how GH has performed over the past day, week, month, or year, review the performance chart and return figures shown on this page.

GH shares can move on Guardant Health's earnings reports, revenue growth, reimbursement decisions from insurers or Medicare, clinical trial outcomes, regulatory clearances, and competitive developments in liquid biopsy and oncology diagnostics. Broader factors such as interest rates, healthcare sector sentiment, and overall market volatility also influence the stock. Each of these can change investor expectations about future cash flows and growth.

Valuation for GH is often assessed using forward-looking metrics because Guardant Health may prioritize growth over current profitability. Investors may review price-to-sales, price-to-book, enterprise value to revenue, and discounted cash flow models, alongside margins, test volume growth, and reimbursement traction. Because the company operates in a rapidly evolving diagnostics market, comparing these metrics with peers and historical ranges can provide useful context. Current valuation multiples for GH are available on this page.

GH shares can be purchased through a brokerage account. Most online brokers allow investors to place market or limit orders for GH during regular Nasdaq trading hours. Some brokers also support fractional shares, which let investors buy a dollar amount rather than a whole share. Before trading, confirm commission fees, order types, and whether extended-hours trading is available for GH. The exact process depends on the brokerage you use.

Key risks for GH include the possibility that Guardant Health's products fail to gain broad reimbursement, clinical adoption slower than expected, or competitors launch superior tests. The company has historically invested heavily in research and sales, which can pressure profitability. Regulatory changes, patent disputes, and reliance on key partnerships also matter. Because GH operates in a specialized healthcare segment, its shares may be more volatile than broad market averages.